Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621377 | 1.00 | PIK3CG (0.44) | PIK3CGEGFR | |
| SCHEMBL316631 | 0.83 | PIK3CG (0.44) | PIK3CGEGFR | |
| SCHEMBL29564212 | 0.78 | MAPK1 (0.38) | PIK3CGEGFR | |
| SCHEMBL3292267 | 0.76 | PIK3CG (0.47) | PIK3CGEGFR | |
| SCHEMBL315448 | 0.74 | PIK3CG (0.37) | PIK3CGEGFR | |
| SCHEMBL3862427 | 0.74 | ALDH1A1 (0.41) | PIK3CGEGFR | |
| SCHEMBL2629406 | 0.74 | PIK3CG (0.37) | PIK3CGEGFR | |
| SCHEMBL2007582 | 0.74 | PIK3CG (0.37) | PIK3CGEGFR | |
| SCHEMBL2007583 | 0.74 | EGFR (0.38) | PIK3CGEGFR | |
| SCHEMBL27898850 | 0.74 | EGFR (0.39) | PIK3CGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4758312-A | Adding colorless electrochemically active compound having positive reduction potential | NALCO CHEMICAL COMPANY (US) | 1988-07-19 | — | — | US | claimed |
| CN-109641905-A | A kind of purifying process of methotrexate (MTX) or its salt | 浙江海正药业股份有限公司 | 2019-04-16 | — | — | CN | disclosed |
| EP-3398948-A2 | 2,4,6,7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | Janus Biotherapeutics, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| CN-107698592-A | A kind of purifying process of methotrexate (MTX) salt | 浙江海正药业股份有限公司 | 2018-02-16 | — | — | CN | disclosed |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| CN-107108629-A | Novel N2, N4, N76-tetrasubstituted pteridine-2, 4, 7-triamines and 2,4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof | 贾纳斯生物治疗有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3183251-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | Janus Biotherapeutics, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016029077-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| CN-101636148-B | Linker-based lecithin microemulsion delivery vehicle | ACOSTA-ZARA EDGAR JOEL | 2014-02-26 | — | — | CN | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2203429-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2010-07-07 | — | — | EP | disclosed |
| CN-101636148-A | Linker-based lecithin microemulsion delivery vehicle | JOEL ACOSTA-ZARA EDGAR | 2010-01-27 | — | — | CN | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| WO-2009057827-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| US-4758312-A | Adding colorless electrochemically active compound having positive reduction potential | NALCO CHEMICAL COMPANY (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0237738-A2 | Method for in situ corrosion detection using electrochemically active compounds | NALCO CHEMICAL COMPANY (US) | 1987-09-23 | — | — | EP | disclosed |
| US-4683035-A | Method for in situ corrosion detection using electrochemically active compounds | NALCO CHEMICAL COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | PIK3CG 3578/4885EGFR 248/4885 |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TLR7, C5, CD4 | PIK3CG 1259/4885EGFR 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.